甲胺作为一种潜在的神经保护剂,可以影响帕金森病的发生
Bhaskar Pal1,2, Niladri Ghatak2, Chowdhury Mobaswar Hossain3
1Department of Pharmacology, Charaktala College of Pharmacy, Charaktala, Mothabari, Malda, West Bengal, India.
概括
甲胺是一种2型糖尿病药物,通过保护神经元,显示出治疗帕金森病 (PD) 的潜力. 需要进一步的研究来证实它对神经退行性疾病的神经保护作用.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,影响多巴胺基神经元,目前没有修改疾病的治疗方法.
- 患PD和2型糖尿病 (T2DM) 之间的潜在联系表明共享的病理途径.
- 甲福明是一种常见的T2DM药物,具有神经保护性质的新证据.
研究的目的:
- 审查有关PD病理学及其与T2DM重叠的文献.
- 检查甲福明的神经保护机制,包括自,α-synuclein调节,线粒体功能和抗炎作用.
- 探索有关甲福明在神经退行症中的潜在益处的流行病学数据.
主要方法:
- 关于帕金森病病理变化的文献综述.
- 对帕金森病和糖尿病之间的重叠研究的分析.
- 检查动物模型和人类临床研究中对甲胺影响的研究.
主要成果:
- 有证据表明,甲福明可以通过与PD相关的各种机制提供神经保护.
- 流行病学研究和动物模型表明,对抗与年龄相关的神经退行症,甲福尔明的潜在益处.
- 存在相互矛盾的结果,强调需要更全面的研究.
结论:
- 梅特福明的多方面的神经保护作用表明,它在帕金森病等神经退行性疾病中可能发挥治疗作用.
- T2DM和PD之间的联系需要进一步调查,其中甲胺作为一个有希望的候选人.
- 进一步的研究至关重要,以确定甲胺在治疗神经元疾病中的有效性和安全性.
相关概念视频
01:24Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
01:15Parkinson's Disease: Overview
708
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
708
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
01:37Neural Regulation
40.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.0K
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K